Bisphenol A is associated with insulin resistance and modulates adiponectin and resistin gene expression in obese

Ciro Menale1,2,3, Anna Grandone4, Carla Nicolucci1,2,5

  • 1Department of Experimental Medicine, Second University of Naples, Naples, Italy.

Pediatric Obesity
|May 18, 2016
PubMed

Insights

Bisphenol A (BPA) exposure in obese children is linked to higher insulin resistance and altered adiponectin levels. BPA affects resistin and adiponectin gene expression in fat cells, suggesting a role in childhood obesity.

Area of Science:

  • Endocrinology
  • Environmental Health
  • Pediatrics

Background:

  • Bisphenol A (BPA) exposure is linked to increased diabetes and obesity in adults.
  • Investigating BPA's role in pediatric metabolic dysfunction is crucial.

Purpose of the Study:

  • To evaluate the association between urinary BPA levels and insulin resistance in obese children.
  • To assess BPA's impact on adiponectin and resistin production and serum concentrations.
  • To examine BPA's effect on adiponectin and resistin gene expression in human adipocytes.

Main Methods:

  • Collected clinical and biochemical data from 141 obese children.
  • Measured serum resistin and adiponectin, and urinary BPA levels.
  • Used quantitative real-time RT-PCR (qPCR) to analyze gene expression in adipocytes.

Main Results:

  • Found a direct association between BPA and insulin resistance (homeostasis model assessment).
  • Observed a strong inverse association between BPA and adiponectin levels.
  • BPA exposure in adipocytes induced resistin expression and suppressed adiponectin expression.

Conclusions:

  • BPA may contribute to insulin resistance in childhood obesity.
  • Urinary BPA levels correlate with insulin resistance independently of BMI.
  • BPA's influence on resistin and adiponectin production in adipose tissue may explain these associations.
Abstract

Related Concept Videos

Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
16.9K
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
360
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
272
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
5.8K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
333